Amgen Inc. $AMGN Stock Position Raised by WBI Investments LLC

WBI Investments LLC boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 193.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,628 shares of the medical research company’s stock after purchasing an additional 1,731 shares during the period. WBI Investments LLC’s holdings in Amgen were worth $742,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of AMGN. Sequoia Financial Advisors LLC boosted its holdings in shares of Amgen by 2.3% during the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after purchasing an additional 3,619 shares during the period. Davis Capital Management acquired a new position in Amgen in the 3rd quarter valued at approximately $1,841,000. D.A. Davidson & CO. increased its stake in Amgen by 2.6% in the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after buying an additional 6,222 shares during the period. Global Wealth Management Investment Advisory Inc. lifted its position in Amgen by 56.2% in the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock worth $3,684,000 after buying an additional 4,699 shares in the last quarter. Finally, Jones Financial Companies Lllp boosted its stake in shares of Amgen by 18.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock valued at $10,888,000 after buying an additional 6,115 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analysts lifted Amgen’s fair value amid optimism around obesity candidate MariTide and execution, which supports a stronger medium-term outlook for earnings. How The Amgen (AMGN) Narrative Is Shifting With MariTide Hopes And Exclusivity Concerns
• Positive Sentiment: Billionaire Ken Fisher increased his Amgen stake, a signal of institutional confidence that can support investor sentiment. Amgen Inc. (AMGN): Billionaire Ken Fisher Doubles Bullish Position
• Neutral Sentiment: Short-interest print shows zero shares (and NaN change), which appears to be a reporting error; it doesn’t offer actionable insight into current positioning.
• Neutral Sentiment: Sector/biotech financing note — Crossbow raised $77M for an oncology T‑cell engager program; industry capital flow can influence sentiment but it doesn’t directly affect Amgen’s fundamentals. Crossbow raises $77M for new cancer immunotherapies
• Negative Sentiment: Report says Amgen will join TrumpRx and offer an ~80% discount on Amjevita — a move that could pressure revenue/margins for that product and raise investor concern about pricing concessions. Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report
• Negative Sentiment: Market headlines reporting that AMGN closed lower amid a broader market uptick — confirms the stock is underperforming today and may be reacting to the items above. Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on AMGN shares. Barclays initiated coverage on shares of Amgen in a research note on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price target on the stock. Leerink Partners reaffirmed a “market perform” rating and issued a $355.00 target price on shares of Amgen in a research report on Thursday, March 5th. UBS Group raised their price target on Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Argus increased their price objective on Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Finally, Freedom Capital lowered Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $354.00.

Amgen Stock Down 2.7%

NASDAQ AMGN opened at $351.48 on Thursday. The stock’s 50 day simple moving average is $359.46 and its 200 day simple moving average is $326.94. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The firm has a market cap of $189.47 billion, a PE ratio of 24.70, a price-to-earnings-growth ratio of 3.58 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.